| Literature DB >> 28464917 |
Young-Nim You1, Myung-Rae Cho2, Ju-Hyung Park1, Gwang-Cheon Park1, Min-Yeong Song3, Jin-Bong Choi3, Chang-Su Na4, Jae-Young Han5, Jeong-Cheol Shin2, Jae-Hong Kim6,7.
Abstract
BACKGROUND: This study aimed to evaluate the quality of reports about randomized controlled trials (RCTs) of scalp acupuncture (SA) for the treatment of vascular dementia (VD).Entities:
Keywords: CONSORT; Randomized controlled trials; STRICTA; Scalp acupuncture; Vascular dementia
Mesh:
Year: 2017 PMID: 28464917 PMCID: PMC5414371 DOI: 10.1186/s13063-017-1945-0
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Rating of overall quality using items from the CONSORT guideline (n = 26)
| Item | Criteria | Description | Number of positive trialsa | Percentage | Cohen’s | 95% CI |
|---|---|---|---|---|---|---|
| 1 | “Randomized” | Study identified as a randomized controlled in the title or abstract | 25 | 96 | 1.00 | 1.00 |
| 2 | Background | Adequate description of the scientific background and explanation of rationale | 14 | 54 | 0.68 | 0.39 to 0.97 |
| 3 | Trial design | Description of trial design (such as parallel, factorial) including allocation ratio | 2 | 8 | 1.00 | 1.00 |
| 4 | Participants | Description of the eligibility criteria for participants | 26 | 100 | 1.00 | 1.00 |
| 5 | Interventions | Details of the interventions intended for each group | 26 | 100 | 1.00 | 1.00 |
| 6 | Outcomes | Definition of primary (and secondary when appropriate) outcome measures | 19 | 73 | 0.78 | 0.49 to 1.07 |
| 7 | Sample size | Description of sample size calculation | 1 | 4 | 0.65 | -0.03 to 1.32 |
| 12 | Statistical methods | Description of the statistical methods used to compare groups for primary outcomes, subgroup analyses, or adjusted analyses | 23 | 88 | 0.78 | 0.36 to 1.20 |
| 13 | Flow chart | Details on the flow of participants through each stage of the trials (number of patients randomly assigned, receiving intended treatment, completing the protocol and analyzed) | 22 | 85 | 0.62 | 0.12 to 1.12 |
| 14 | Recruitment | Dates defining the periods of recruitment and follow up | 21 | 81 | 0.71 | 0.32 to 1.10 |
| 17 | Outcomes and estimation | For each primary and secondary outcome, a summary of results for each group is given, and the estimated effect size and its precision (for example, 95% CI) | 20 | 77 | 0.75 | 0.42 to 1.08 |
| 18 | Ancillary analyses | Clear statement of whether subgroup/adjusted analyses were prespecified or exploratory | 0 | 0 | 1.00 | 1.00 |
| 19 | Harms | Description of all important adverse events in each group | 2 | 8 | 0.63 | 0.13 to 1.12 |
CONSORT Consolidated Standards of Reporting Trials. aPositive trials, the information for each item was stated so 1 point was given
Rating of overall quality using items from the STRICTA guideline (n = 26)
| Item | Criteria | Description | Number of positive trialsa | Percentage | Cohen’s | 95% CI |
|---|---|---|---|---|---|---|
| 1 | Acupuncture rationale | (1a) Style of acupuncture (e.g., traditional Chinese medicine, Japanese, Korean, Western medical, five element, ear acupuncture, etc.) | 26 | 100 | 1.00 | 1.00 |
| (1b) Reasoning for treatment provided, based on historical context, literature sources and/or consensus methods, with references where appropriate | 22 | 85 | 0.84 | 0.52 to 1.15 | ||
| (1c) Extent to which treatment was varied | 1 | 4 | 1.00 | 1.00 | ||
| 2 | Details of needling | (2a) Number of needle insertions per subject per session (mean and range where relevant) | 2 | 8 | 1.00 | 1.00 |
| (2b) Names (or location if no standard name) of points used (uni-/bilateral) | 26 | 100 | 1.00 | 1.00 | ||
| (2c) Depth of insertion, based on a specified unit of measurement or on a particular tissue level | 17 | 65 | 0.72 | 0.43 to 1.02 | ||
| (2d) Responses sought (e.g., | 20 | 77 | 0.88 | 0.66 to 1.10 | ||
| (2e) Needle stimulation (e.g., manual or electrical) | 13 | 50 | 0.52 | 0.19 to 0.86 | ||
| (2f) Needle retention time | 21 | 81 | 0.87 | 0.61 to 1.12 | ||
| (2 g) Needle type (diameter, length and manufacturer or material) | 22 | 85 | 0.84 | 0.52 to 1.15 | ||
| 3 | Treatment regimen | (3a) Number of treatment sessions | 23 | 88 | 0.78 | 0.36 to 1.20 |
| (3b) Frequency and duration of treatment sessions | 25 | 96 | 1.00 | 1.00 | ||
| Other components of treatment | (4a) Details of other interventions administered to the acupuncture group (e.g., moxibustion, cupping, herbs, exercises, lifestyle advice) | 15 | 58 | 0.67 | 0.37 to 0.97 | |
| (4b) Setting and context of treatment, including instructions to practitioners, and information and explanations to patients | 1 | 4 | 0.65 | -0.03 to 1.32 | ||
| 5 | Practitioner background | (5) Description of participating acupuncturists (qualification or professional affiliation, years in acupuncture practice, other relevant experience) | 22 | 77 | 0.74 | 0.43 to 1.08 |
| 6 | Control or comparator interventions | (6a) Rationale for the control or comparator in the context of the research question, with sources that justify the choice(s) | 9 | 35 | 0.76 | 0.51 to 1.02 |
| (6b) Precise description of the control or comparator. If sham acupuncture or any other type of acupuncture-like control is used, provide details as for items 1–3 above | 26 | 100 | 1.00 | 1.00 |
STRICTA Standards for Reporting Interventions in Controlled Trials of Acupuncture. aPositive trials, the information for each item was stated so 1 point was given
Quality of key methodological items (n = 26)
| Item | Criteria | Description | Number of positive trialsa | % | Cohen’s | 95% CI |
|---|---|---|---|---|---|---|
| 8 | Randomization | Description of the method used to generate the random sequence | 14 | 54 | 0.68 | 0.39 to 0.97 |
| 9 and 10 | Allocation concealment and implementation | Description of the method used to implement the random allocation sequence assuring the concealment until interventions are assigned | 3 | 12 | 0.84 | 0.52 to 1.15 |
| 11 | Blinding | Whether or not participants, those administering the interventions, or those assessing the outcomes were blinded to group assignment | 3 | 12 | 1.00 | 1.00 |
| 15 | Baseline data | An outline of baseline demographic and clinical characteristics of each group | 11 | 42 | 0.92 | 0.77 to 1.07 |
| 16 | Intent-to-treat analysis | No. of participants in each group included in each analysis and whether it was done by “intention to treat” | 3 | 12 | 0.71 | 0.32 to 1.10 |
aPositive trials, the information for each item was stated so 1 point was given
Fig. 1Flowchart of the article selection process. RCT randomized controlled trial
Fig. 2Number of publications